Onasemnogene abeparvovec

Onasemnogene Abeparvovec

Onasemnogene abeparvovec

Onasemnogene abeparvovec, marketed under the brand name Zolgensma, is a gene therapy used to treat spinal muscular atrophy (SMA), a severe neuromuscular disorder caused by mutations in the SMN1 gene. This therapy is designed to address the underlying genetic cause of SMA by delivering a functional copy of the SMN1 gene to the patient's motor neurons.

Mechanism of Action

Onasemnogene abeparvovec utilizes a non-replicating adeno-associated virus (AAV) vector, specifically AAV9, to deliver the SMN1 gene. The AAV9 vector is chosen for its ability to cross the blood-brain barrier and target motor neurons effectively. Once inside the cell, the vector releases the SMN1 gene, which then integrates into the host cell's genome, allowing for the production of the survival motor neuron (SMN) protein. This protein is crucial for the maintenance and function of motor neurons, which are responsible for muscle movement.

Administration

The therapy is administered as a one-time intravenous infusion. The dosage is determined based on the patient's weight, and the infusion typically lasts about 60 minutes. Prior to administration, patients may receive corticosteroids to mitigate potential immune responses to the viral vector.

Efficacy

Clinical trials have demonstrated that onasemnogene abeparvovec can significantly improve motor function in infants with SMA, particularly those with SMA type 1, the most severe form of the disease. Treated patients have shown improvements in motor milestones such as sitting, crawling, and walking, which are typically not achieved in untreated individuals with SMA type 1.

Safety and Side Effects

The most common side effects of onasemnogene abeparvovec include elevated liver enzymes, vomiting, and decreased platelet counts. Serious liver injury has been reported, necessitating regular monitoring of liver function following treatment. Patients are also monitored for signs of thrombocytopenia and cardiac issues.

Regulatory Approval

Onasemnogene abeparvovec received FDA approval in May 2019 for the treatment of pediatric patients less than two years of age with SMA. It has also been approved by the European Medicines Agency (EMA) and other regulatory bodies worldwide.

Cost and Accessibility

The therapy is one of the most expensive drugs on the market, with a list price of over $2 million per treatment. Despite its high cost, it is considered a breakthrough in the treatment of SMA due to its potential to alter the course of the disease with a single administration.

Related Pages

• Spinal muscular atrophy
• Gene therapy
• Adeno-associated virus
• SMN1